#### COVAX Allocation status and plan for Q4

- 7 Allocation rounds have been run to date for a total of 381M doses, and an additional 145M doses have been donated through COVAX
- 297M doses have arrived in 141 countries and territories, as of Sept 21st
- To date, **26 participants** have a coverage **below 10%** (from all sources of supply, COVAX and other) and an additional 23 are below 20%
- In light of this, the allocation mechanism has been adapted to target participants with low coverage from all sources of supply

#### Overview of Allocation Rounds to date and until end of 2021

Allocations to come by end of 2021

Rounds Publication date/(content)	Feb 21 (Pfizer 1st wave)	Mar 21 (AZ/SII Feb- May round)	Mar 21 (Pfizer Q2)	Jun 21 (AZ 2 <sup>nd</sup> doses)	Jul 21 (Pfizer Q3)	Jul 21 (Sinopharm, Sinovac Q3)	Sept 21 (Oct. round <sup>2</sup> )	Sept 21 (Nov-Dec. round)	TBD (Nov-Dec. round)
Volume (M doses)	1.2	105	14.1	17.1	72.1	95.6	75.9	High certainty Nov-Dec supply	Residual Nov-Dec supply
Products allocated	Pfizer	AZ, AZ-SII	Pfizer	AZ	Pfizer	Sinopharm, Sinovac	AZ, J&J, Pfizer, Moderna, Sinopharm	AZ, J&J, Pfizer, Moderna	Clover, Novavax, TBC
Methodology	Standard allocation, based on participant population						Participants are selected into rounds based on total coverage (from all sources) to boost lower coverage participants		
<ol> <li>Depending on EUL of Clover and Novavax vaccines</li> <li>Validated by the IAVG and approved By the WHO DDG on 14 September</li> </ol>									

### Changes made to allocation methodology, with an exceptional round in October for participants with lower coverage from all sources of supply

**ILLUSTRATIVE** 

All participants below 20% COVAX coverage Participants with lower overall coverage

Q1-Q3 supply

October supply

November – December supply

Rounds



**Current allocation** mechanism, proportional allocation, accounts for **COVAX** coverage

Exceptional<sup>1</sup> round, October volumes, allocation only to participants with low coverage from all sources of supply

Allocation mechanism for November and December **volumes**, reserve 50% of doses for those with **low** coverage and remaining 50% for all participants below 20% COVAX coverage


Supply for Allocation

100% of supply allocated proportionally to all participants below 20% **COVAX** coverage

**Participant** coverage (all sources)



100% of supply allocated exceptionally to participants below 10% coverage, all sources



Step 1

50% allocated to participants below 20% coverage, all sources



Step 2

50% of supply allocated proportionally to all participants below 20% **COVAX** coverage




Alternative paths are being explored aiming to support participants with lower coverage in maximizing their supply until end of 2021

For exceptional/dedicated steps of rounds: list of participants selected for a round will be adjusted by CRD: capping volumes for participants with absorptive capacity information and adding participants who are close to the coverage cut-off mark but have current momentum in administering doses

## Zoom -Participants prioritized for R7

Out of 89 AMC and 73 SFPs total in the COVAX facility

# Participants were prioritised if they had both a low coverage and the absorption capacity to receive and deploy October volumes<sup>1</sup>



<sup>1.</sup> Participants were prioritised if they had: absorbed more than 75% of doses; no shipments in last month; not featured on the implementation watch list; and/or do not have other sources of doses but under 10% coverage

COVAX 4

<sup>2.</sup> Participants were reviewed below 14.5% total coverage from all sources, incl. participants above original round benchmark of 10% to account for current momentum in administering doses